Search

Your search keyword '"Bilgin, Yavuz M"' showing total 3 results
Start Over Author "Bilgin, Yavuz M" Publisher american society of clinical oncology
3 results on '"Bilgin, Yavuz M"'

1. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Published
2024

2. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.

Author

Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, and Oosterveld, Margriet

Published
2021
Full Text
View/download PDF

3. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.

Author

Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, and Schaapveld M

Subjects
Humans, Female, Adolescent, Adult, Middle Aged, Young Adult, Antibiotics, Antineoplastic adverse effects, Incidence, Netherlands epidemiology, Risk Factors, Hodgkin Disease epidemiology, Hodgkin Disease drug therapy, Doxorubicin adverse effects, Doxorubicin administration & dosage, Breast Neoplasms epidemiology, Breast Neoplasms drug therapy, Cancer Survivors statistics & numerical data
Abstract

Purpose: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages., Methods: We assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses., Results: After a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m 2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m 2 doxorubicin ( P trend = .004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR] age <21 years , 1.5 [95% CI, 0.9 to 2.6]; HR age ≥21 years , 1.3 [95% CI, 0.9 to 1.9) or chest RT (HR without mantle/axillary field RT , 1.9 [95% CI, 1.06 to 3.3]; HR with mantle/axillary field RT , 1.2 [95% CI, 0.8 to 1.8])., Conclusion: This study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results